CD19 Antibody [CVID3/429] | 33-284

CD19 Antibody [CVID3/429] | 33-284 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human, Monkey

Homology: N/A

Immunogen: Human CD19 recombinant protein was used as immunogen for this CD19 antibody.

Research Area: Cancer, Immunology, Signal Transduction

Tested Application: WB, Flow, IF

Application: Flow Cytometry: 0.5-1 ug/million cells
Immunofluorescence: 0.5-1 ug/ml


Variations in protocols, secondaries and substrates may require the CD19 antibody to be titered up or down for optimal performance.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Protein G affinity chromatography

Clonality: Monoclonal

Clone: CVID3/429

Isotype: IgG1, kappa

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12, CD19, CD19

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: CD19 is expressed on follicular dendritic cells and B cells. It is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. It primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. [Wiki]